Cardiol Therapeutics Inc (CRDL)

09:30 AM

Cardiol Therapeutics (Nasdaq: CRDL) outlines 2026 virtual shareholder meeting - Stock Titan

09:30 AM

May 22, 2026

CRDL Stock Price, Quote & Chart | CARDIOL THERAPEUTICS INC-A (NASDAQ:CRDL) - ChartMill

May 22, 2026

May 21, 2026

Cardiol Therapeutics Inc (TSX:CRDL) Stock Price & 30 Year Financial Data - GuruFocus

May 21, 2026

May 19, 2026

CCORF Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Maintains Target Price $8 - Moomoo

May 19, 2026

May 16, 2026

(CRDL) On The My Stocks Page (CRDL:CA) - Stock Traders Daily

May 16, 2026

May 15, 2026

[SCHEDULE 13G/A] Cardiol Therapeutics Inc. Amended Passive Investment Disclosure - Stock Titan

May 15, 2026

May 15, 2026

Here's Why We're Watching Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation - Yahoo Finance

May 15, 2026

May 14, 2026

Cardiol Therapeutics Inc.Class A Common Shares (NQ: CRDL - FinancialContent

May 14, 2026

May 14, 2026

Stocks in play: Cardiol Therapeutics Inc. - The Globe and Mail

May 14, 2026

May 14, 2026

TradingKey - TradingKey

May 14, 2026

May 14, 2026

Cardiol Therapeutics to Present Pipeline at H.C. Wainwright BioConnect Conference at NASDAQ - TipRanks

May 14, 2026

May 14, 2026

Cardiol Therapeutics (CRDL) joins H.C. Wainwright BioConnect investor Fireside Chat at NASDAQ - Stock Titan

May 14, 2026

May 14, 2026

Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ - PR Newswire

May 14, 2026

May 12, 2026

H.C. Wainwright Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Maintains Target Price $9 - Moomoo

May 12, 2026

May 11, 2026

Cardiol Therapeutics Reports Higher Q1 2026 Loss but Stronger Cash Position - TipRanks

May 11, 2026

May 11, 2026

Cardiol Therapeutics (CRDL) extends cash runway and advances late-stage heart trials - Stock Titan

May 11, 2026

May 11, 2026

Cardiol Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 11, 2026

May 08, 2026

Cardiol Therapeutics Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView

May 08, 2026

May 07, 2026

Cardiol Therapeutics’ Phase II MAvERIC Pericarditis Data Accepted by JAHA as Phase III Trial Nears Completion - TipRanks

May 07, 2026

May 07, 2026

Phase II MAvERIC data for CardiolRx in pericarditis to appear in JAHA for Cardiol (NASDAQ: CRDL) - Stock Titan

May 07, 2026

May 07, 2026

Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association - PR Newswire

May 07, 2026

May 06, 2026

Cardiol Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus

May 06, 2026

May 01, 2026

CRDL.CA Stock Price, Quote & Chart | CARDIOL THERAPEUTICS INC-A (TSX:CRDL) - ChartMill

May 01, 2026

Apr 29, 2026

Phase III Trial Enrollment Reached (75%) for Promising Anti-Inflammatory and Anti-Fibrotic Cardiac Therapies by Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) - Barchart.com

Apr 29, 2026

Apr 29, 2026

Phase III Trial Enrollment Reached (75%) for Promising - openPR.com

Apr 29, 2026

Apr 29, 2026

User - The Chronicle-Journal

Apr 29, 2026

Apr 28, 2026

Ellis Martin Report: Cardiol Therapeutics (TSE.CRDL) CEO David Elsley on Breakthrough Heart Disease Treatment - ABN Newswire

Apr 28, 2026

Apr 28, 2026

Cardiol Therapeutics (CRDL) Expands MAVERIC Trial with New Clini - GuruFocus

Apr 28, 2026

Apr 28, 2026

Cardiol Therapeutics expands Phase III trial to 25 sites By Investing.com - Investing.com India

Apr 28, 2026

Apr 28, 2026

Cardiol Therapeutics expands Phase III trial to 25 sites - Investing.com UK

Apr 28, 2026

Apr 28, 2026

Cardiol Therapeutics Expands U.S. Phase III MAVERIC Trial Network as Enrollment Reaches 75% - TipRanks

Apr 28, 2026

Apr 28, 2026

Cardiol Therapeutics (NASDAQ: CRDL) expands U.S. MAVERIC Phase III trial network - Stock Titan

Apr 28, 2026

Apr 28, 2026

Cardiol Therapeutics Inc. Expands Maveric Phase III Trial Network and Provides Clinical Updates on Cardiolrx - marketscreener.com

Apr 28, 2026

Apr 27, 2026

Correction: Positive Results on MAVERIC Phase 2 and Published ARCHER Study Presented by the Company CEO in Live Interview with Barchart: Cardiol Therapeutics Inc. (NASDAQ: CRDL) - Barchart.com

Apr 27, 2026

Apr 27, 2026

Correction: Positive Results on MAVERIC Phase 2 and Published - openPR.com

Apr 27, 2026

Apr 23, 2026

Positive Results on MAVERIC Phase III Trial and Published ARCHER Study Presented by the Company CEO in Live Interview with Barchart: Cardiol Therapeutics Inc. (NASDAQ: CRDL) - Barchart

Apr 23, 2026

Apr 23, 2026

Positive Results on MAVERIC Phase III Trial and Published ARCHER - openPR.com

Apr 23, 2026

Apr 23, 2026

CRDL (Cardiol Therapeutics Inc.) Q4 2025 narrower than expected loss lifts shares more than 7 percent higher today.Revenue Diversification - Xã Thanh Hà

Apr 23, 2026

Apr 22, 2026

Is Cardiol (CRDL) stock sensitive to volatility (Drops Sharply) 2026-04-22Investment Community Signals - Cổng thông tin điện tử tỉnh Lào Cai

Apr 22, 2026

Apr 22, 2026

Metro Q2 2026 Earnings Rise On Margins, Buybacks And Pharmacy Growth - thedeepdive.ca

Apr 22, 2026

Apr 21, 2026

Moderna to Present at Upcoming Conferences in May 2026 - Investing News Network

Apr 21, 2026

Apr 21, 2026

Cardiol Therapeutics (TSE:CRDL) Sets New 1-Year HighHere's Why - MarketBeat

Apr 21, 2026

Apr 19, 2026

Fixing Heart Disease Tied to Sudden Death in Young People | David ElsleyCardiol Therapeutics - thedeepdive.ca

Apr 19, 2026

Apr 18, 2026

Cardiol Therapeutics (TSE:CRDL) Trading Up 7.9%Here's What Happened - MarketBeat

Apr 18, 2026

Apr 15, 2026

Cardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis Promise - MarketBeat

Apr 15, 2026